Canerpaturev is under clinical development by Takara Bio and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Canerpaturev’s likelihood of approval (LoA) and phase transition for Metastatic Melanoma took place on 30 Nov 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Canerpaturev Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Canerpaturev overview

Canerpaturev (HF-10, Msc2) is under development for the treatment of cancer including unresected or metastatic malignant melanoma. The drug candidate is administered intratumorally. It is an attenuated, replication-competent mutant strain of Herpes Simplex Virus type 1 (HSV1). The drug candidate was also under development for the treatment of breast cancer, squamous cell carcinoma of the head and neck, metastatic melanoma, pancreatic cancer and squamous cell carcinoma of skin cancer.

Takara Bio overview

Takara Bio (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company develops and researches reagents for genome engineering and analysis, technology used for gene therapy and natural health food products. It offers various medical devices includes analytical reagents, single cell analysis system and genome editing research reagents, among others. Takara services includes instrument services, oem and custom enzyme manufacturing, stem cell services, technical support, shipping and delivery, partnering and licensing and online tools. The company acts as a contract service provider involved in providing services in developing degenerative medicines and gene analysis services. Takara is headquartered in Kusatsu, Shiga, Japan.

Quick View Canerpaturev LOA Data

Report Segments
  • Innovator
Drug Name
  • Canerpaturev
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Takara Bio
  • Originator: Nagoya University
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.